Zaragoza-Infante Laura, Agathangelidis Andreas, Iatrou Anastasia, Junet Valentin, Pechlivanis Nikos, Karypidou Maria, Koletsa Triantafyllia, Karakatsoulis Giorgos, Bruscaggin Alessio, Davis Zadie, Spina Valeria, Verney Aurelie, Polychronidou Eleftheria, Psomopoulos Fotis, Oscier David, Traverse-Glehen Alexandra, Papaioannou Maria, Ghia Paolo, Rossi Davide, Chatzidimitriou Anastasia, Stamatopoulos Kostas
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece.
First Department of Medicine Aristotle University of Thessaloniki Thessaloniki Greece.
Hemasphere. 2025 May 27;9(5):e70147. doi: 10.1002/hem3.70147. eCollection 2025 May.
Almost one-third of all splenic marginal zone lymphoma (SMZL) cases express B-cell receptor immunoglobulin (BcR IG) encoded by the IGHV1-204 gene, implicating antigen selection in disease ontogeny. Evidence supporting this notion mostly derives from low-throughput sequencing approaches, which have limitations in capturing the full complexity of the BcR IG gene repertoire. This hinders the comprehensive assessment of the subclonal architecture of SMZL as shaped by antigen selection. To address this, we conducted a high-throughput immunogenetic investigation of SMZL aimed at the comprehensive characterization of the somatic hypermutation (SHM) and intraclonal diversification within the IG genes. We identified significant differences in the SHM and ID profiles between cases expressing the IGHV1-204 gene and those expressing other IGHV genes. Specifically, IGHV1-204 cases displayed (i) targeted SHM resulting in recurrent replacement SHMs, and (ii) significantly more pronounced intraclonal diversification, reflecting ongoing antigen selection. Overall, our findings suggest that SMZL cases expressing the IGHV1-204 gene have a distinct immunogenetic signature shaped by microenvironmental pressure on the clonotypic BcR IG, corroborating the idea that this group may represent a distinct molecular variant of SMZL.
几乎三分之一的脾边缘区淋巴瘤(SMZL)病例表达由IGHV1-204基因编码的B细胞受体免疫球蛋白(BcR IG),这表明抗原选择在疾病发生过程中起作用。支持这一观点的证据大多来自低通量测序方法,这些方法在捕捉BcR IG基因库的全部复杂性方面存在局限性。这阻碍了对由抗原选择塑造的SMZL亚克隆结构的全面评估。为了解决这个问题,我们对SMZL进行了高通量免疫遗传学研究,旨在全面表征IG基因内的体细胞高频突变(SHM)和克隆内多样化。我们发现表达IGHV1-204基因的病例与表达其他IGHV基因的病例在SHM和ID谱方面存在显著差异。具体而言,IGHV1-204病例表现出(i)靶向SHM导致反复出现的置换SHM,以及(ii)明显更显著的克隆内多样化,反映了持续的抗原选择。总体而言,我们的研究结果表明,表达IGHV1-204基因的SMZL病例具有由克隆型BcR IG上的微环境压力塑造的独特免疫遗传特征,证实了这一组可能代表SMZL的一种独特分子变体的观点。